Navigation Links
Fulgent Therapeutics Announces Their Comprehensive Hereditary Cancer Test Including BRCA1 and BRCA2 Analysis

Temple City, CA (PRWEB) June 14, 2013

Fulgent Therapeutics LLC, a CLIA Certified Laboratory, announces the inclusion of BRCA1 and BRCA2 analysis to its Hereditary Cancer Panel. Fulgent Therapeutics is excited to add these key targets, making it the most comprehensive test for cancer risk assessment available.

Fulgent Therapeutics Hereditary Cancer Panel detects mutations in 49 known cancer predisposition genes, now including BRCA1 and BRCA2. “We use well defined processes, robust bioinformatics, and Next Generation Sequencing to provide our clients with a comprehensive look at a true myriad of genes,” according to Dr. Harry Gao, Lab Director for Fulgent Therapeutics.

Personalized medicine demands that we examine diseases in new ways and deploy innovative tools to view all angles of the patient’s health and potential diseases. Fulgent Therapeutics Hereditary Cancer Panel provides patients and physicians with the information to assess their risks and guide their care. “Making molecular diagnostics more comprehensive and at the same time more affordable is our goal,” says Dr. Gao.

Fulgent Therapeutics president, Ming Hsieh stated, “We agree with the Supreme Court’s decision and we look forward to providing physicians with better tools and more options to help their patients."

Fulgent Therapeutics is currently working on panels for more than just cancer. The Next Generation panels for many inherited disease including cardiology, pediatrics, and neurology will provide physicians with more information than previously available.

The release date for the Hereditary Cancer Panel, including BRCA1 and BRCA2, will be available July 8, 2013. Fulgent Therapeutics anticipates that it will provide another first to the industry by getting the 49-gene panel’s price under $3,000.

Additional information: info(at)fulgent-therapeutics(dot)com or 626-350-0537 x106.

About Fulgent Therapeutics LLC: Founded in 2011, Fulgent Therapeutics, LLC is a pharmaceutical and Next Generation molecular diagnostics company focusing on developing and commercializing innovative cancer therapeutics and Next Generation diagnostics. The company has a number of improved generic and innovated drug candidates in its product pipeline for treating a broad range of cancers including those of the breast, lung, ovary, colon, and pancreas. In addition, Fulgent Therapeutics has developed an innovative line of Next Generation diagnostics for both somatic and hereditary diseases.

Fulgent Therapeutics LLC
4978 Santa Anita Ave, Ste 205
Temple City, CA

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Mainz University obtains new CRC Nanodimensional polymer therapeutics for tumor therapy
2. MDA Awards Valerion Therapeutics $1.2 Million to Continue Myotubular Myopathy Research
3. Corena Therapeutics Launched Coresatin, a Nonsteroidal Cream Used to Treat Critical Skin Conditions and Infections
4. Global Peptide Therapeutics Market - New Market Research Report Published by Transparency Market Research
5. Liver Diseases Therapeutics Market - New Industry Research Report Published by Transparency Market Research
6. Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
7. Scientist receives $2.8 Million to study cell signaling mechanism and develop potential therapeutics
8. Cancer vaccine Special Focus series published in Human Vaccines & Immunotherapeutics
9. Research shows potential of microneedles to target therapeutics to the back of the eye
10. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
11. FORMA Therapeutics teams with TGen Drug Development
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... Growth in medical ... due to decreases in utilization of hospital and nonhospital care, according to a recent ... Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim with more ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015—Since the ... in scientific research and discoveries, leading us to better understand the disease’s behavior. ... those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS Day” provides insight ...
(Date:12/1/2015)... ... ... It’s official: Tattoo taboo is a thing of the past. One in ... whopping one in three aged 18 to 25 is inked). As tattoos transition to ... In fact, RealSelf , the world’s largest community for learning and sharing information ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015 WellStar Health System has ... Texas -based Tenet Healthcare,s five metro ... approved the strategic move following the conclusion of the ... clinical care models and patient safety programs that have ... to new communities. --> ...
(Date:12/1/2015)... 2015  Eyeon Therapeutics has received a Notice ... based on a charged hydrophilic polymer developed at ... product has been shown to be safe and ... Mark Mitchnick , MD, CEO states, "This second ... polymers in conjunction with a therapeutic agent.  Nanoparticles ...
(Date:12/1/2015)... 1, 2015 Pharma Tech Outlook recently conducted ... Clinical Data Management Solution Providers - 2015 .  After ... comprising CEOs, CIOs, VCs, analysts, and the Pharma Tech ... of top 10 clinical data management solution providers (check ... 14 and 36 respectively). --> ...
Breaking Medicine Technology: